Alzheimer's disease (AD) is a complex neurodegenerative disorder that develops over decades. AD brain proteomics reveals vast alterations in protein levels and numerous altered biologic pathways. Here, we compare AD brain proteome and network changes with the brain proteomes of amyloid β (Aβ)-depositing mice to identify conserved and divergent protein networks with the conserved networks identifying an Aβ amyloid responsome. Proteins in the most conserved network (M42) accumulate in plaques, cerebrovascular amyloid (CAA), and/or dystrophic neuronal processes, and overexpression of two M42 proteins, midkine (Mdk) and pleiotrophin (PTN), increases the accumulation of Aβ in plaques and CAA. M42 proteins bind amyloid fibrils in vitro, and MDK and PTN co-accumulate with cardiac transthyretin amyloid. M42 proteins appear intimately linked to amyloid deposition and can regulate amyloid deposition, suggesting that they are pathology modifiers and thus putative therapeutic targets. We posit that amyloid-scaffolded accumulation of numerous M42+ proteins is a central mechanism mediating downstream pathophysiology in AD.
Cellulase containing nanobiocatalysts have been useful as an extraction tool based on their ability to disrupt plant cell walls. In this work, we investigate the effect of nanoparticle composition and chemical linkage towards immobilized cellulase activity. Cellulase nanoconstructs have been prepared, characterized and compared for their loading efficiencies with standard assays and enzyme kinetics and correlate well with the cognate loading efficiencies. Application of the cellulase-immobilized nanoparticles on onion skins results in release of a distinctive composition of polyphenols. The aglycosidic form of quercetin is the dominant product of onion skin hydrolysis affected by cellulase nanobiocatalysts. Chitosan-coated iron oxide nanoparticles with APTES-conjugated cellulase are found to be most effective for polyphenol release and for transformation of glycosidic to aglycosidic form of quercetin. These results shed light on the activity of immobilized cellulase beyond their role in cell wall disruption and are important for the practical application of cellulase nanobiocatalysts.
1 December 2020 in European Journal of Medicinal Chemistry
Tau protein is found abundantly in neurofibrillary tangles in Alzheimer's disease (AD). The longest human tau isoform (2N4R) has 44 lysine residues. Several lysine‐based post‐translational modifications (PTMs) such as glycation, acetylation, ubiquitination, and sumoylation have been implicated not only in AD, but also in other tauopathies. Carbamylation is one such lysine neutralizing age‐related nonenzymatic PTM which can modulate the aggregation propensity of tau. In this work, we have studied the aggregation potential of lysine‐rich regions of tau upon carbamylation which do not aggregate in their native form. Using an array of biophysical and microscopic analyses, such as ThT kinetic assay, fluorescence microscopy, Congo red staining, and scanning electron microscopy, we demonstrate that peptides derived from four of five such regions exhibit robust fibrillar amyloid formation. These regions are found in the N‐terminal projection domain that encompasses proline‐rich domain (148–153 and 223–230), repeat domain R1 (253–260), as well as fibrillary core region (368–378), and can be described as hidden aggregation hot‐spots which become activated upon carbamylation. We have further compared the impact of carbamylation with acetylation on the aggregation propensity of lysine‐rich peptide (254KKVAVV259) using biophysical experiments and molecular dynamics simulations and deduced that carbamylation is a much stronger driver of aggregation than acetylation. Our findings may offer more insight into amyloid fibrils' interaction with hidden aggregation‐prone nucleating sequences that act as hot‐spots for inducing tau fibrillation.